Lilly and NextCure pen immuno-oncology deal; Lilly terminates deal
Eli Lilly & Co. and NextCure Inc. partnered to discover and develop new immuno-oncology therapies utilizing NextCure’s FIND-IO (Functional, Integrated, NextCure Discovery in Immuno Oncology) platform.
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.